Device Week, 4 October 2019 – Demant Group Recovers From Cyber-Attack; TCT Conference Highlights
Executive Summary
In this week's podcast, senior reporter Catherine Longworth provides an update on how the Demant Group is recovering from a ransomware attack that forced the Danish hearing-aid manufacturer to shut down its IT systems, and deputy editor Reed Miller reviews the highlights of the clinical trial presentations at the recent Transcatheter Cardiovascular Therapeutics (TCT) conference in San Francisco.
Listen to the podcast via the player below:
Medtech Insight articles addressing topics discussed in this episode:
-
TCT 2019: Boston Scientific's Acurate Neo TAVR Misses Endpoint In SCOPE I
-
TCT 2019: New COAPT Results Support, Durability And Cost-Effectiveness Of Abbott’s MitraClip
-
TCT 2019: IDEAL LM Inconclusive, While Onyx ONE Boosts Polymer-Based DES
-
TCT 2019: Evolve Short DAPT And Model U-SUS Study Show Short DAPT Was Comparable To Longer-Term DAPT
-
TCT 2019: Five-Year PARTNER 2A Results Support TAVR In Most Intermediate Risk Patients
-
TCT 2019: TRILUMINATE Six-Month Results Support Abbott’s TriClip
-
TCT 2019: One-Year PARTNER 3 Outcomes Show Better Quality Of Life With TAVR